A Phase 3 interventional study of Nivolumab and Ipilimumab in Melanoma, sponsored by Bristol-Myers Squibb. Completed at 16 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-17.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 62 under way, 9 of them phase 3. Nivolumab · Melanoma.
Among the 142 studies testing nivolumab in Melanoma, this one is the 40th largest by enrollment, is one of 16 that started in 2016, is one of 19 in phase 3, and was the 38th registered.
3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.
Browse Melanoma studies →32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+
Swiss Cancer Institute · Sites in Switzerland
Ages 18+
Melanoma and Skin Cancer Trials Limited · Sites in Australia
Ages 18+
Radboud University Medical Center · Sites in Netherlands
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 94 · Phase 3 20 · Phase 4 4
First in 2006; this study’s year is marked. 16 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 50 across the 142 interventional studies. Of the 63 that completed or were terminated, 35 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 142 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
111 studies in Melanoma by Bristol-Myers Squibb: 3 open now, 9 under way, 3 of them phase 3. Of 90 finished, 41 (46%) have results posted.
Among the 111 studies in Melanoma by Bristol-Myers Squibb, this one is the 39th largest by enrollment of the 75 interventional ones that give a count, is one of 12 that started in 2016, is one of 21 in phase 3, and was the 72nd registered.
Bristol-Myers Squibb’s Melanoma studies by the year they started, since 2002.
13 of the studies testing nivolumab in Melanoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04309409Phase 3University Hospital, EssenAdjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma | 2027-09 |
| NCT06712927Stanford UniversityTrial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | 2026-11 |
| NCT07155317Emory UniversityTime-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | 2026-12-31 |
| NCT03685890Vastra Gotaland RegionEvaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion | 2026-12-31 |
| NCT05136196National Cancer Institute (NCI)BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | 2027-01-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 142 studies testing nivolumab in Melanoma, from their registry updates:
Among Bristol-Myers Squibb’s 111 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a safety and efficacy study of different administration regimens of nivolumab plus Ipilimumab in subjects with previously untreated, unresectable or metastatic melanoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Followed by Nivolumab monotherapy
Biological: Nivolumab · Biological: Ipilimumab
Followed by Nivolumab monotherapy
Biological: Nivolumab · Biological: Ipilimumab
-Specified dose on specified days
-Specified dose on specified days
Percentage of Participants Affected by Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ)
This outcome describes the percentage of participants experiencing at least 1 AE in the MedDRA Anaphylactic Reaction broad scope SMQ. Such AEs include any acute systemic reaction characterized by a large list of terms, including (but not limited to) pruritus, urticaria, flushing, hypotension, respiratory distress, and vascular insufficiency. It also includes other signs and symptoms such as asthma, choking sensation, coughing, sneezing, and difficulty breathing due to laryngeal spasm and/or bronchospasm. Less frequent clinical presentations are also captured and include hyperventilation, sensation of foreign body, and ocular edema.
Time frame: Within 2 days from administration of any of the 4 doses in part 1 period (approximately 12 weeks)
Percentage of Participants Affected by AEs in the Narrow Scope MedDRA Anaphylactic Reaction SMQ
This outcome describes the percentage of participants experiencing at least 1 AE in the MedDRA Anaphylactic Reaction narrow scope SMQ. The narrow scope SMQ is composed of a large list of terms, including (but not limited to) anaphylactic shock and reaction, shock and shock symptoms, and circulatory collapse, among the others.
Time frame: Within 2 days from administration of any of the 4 doses in part 1 period (approximately 12 weeks)
Percentage of Participants Affected by Hypersensitivity/Infusion Reaction Select AEs
This outcome describes the percentage of participants experiencing at least 1 AE in the Hypersensitivity/Infusion select AEs category. The select AEs consist of a list of preferred terms defined by the Sponsor and represent AEs with a potential immune-mediated etiology. The following 5 MedDRA preferred terms are included in the hypersensitivity/infusion reaction select AE category: Anaphylactic Reaction, Anaphylactic Shock, Bronchospasm, Hypersensitivity, and Infusion Related Reaction
Time frame: Within 2 days from administration of any of the 4 doses in part 1 period (approximately 12 weeks)
Percentage of Participants Affected by All Causality Grade 3 - 5 AEs
This outcome describes the percentage of participants who experienced at least 1 AE of Grade 3 or higher defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria
Time frame: From initial dose of study treatment and within 30 days of the last dose of study treatment (approximately 25 months)
Percentage of Participants Affected by Drug-related Grade 3 - 5 AEs
This outcome describes the percentage of participants who experienced at least 1 Drug-related AE of Grade 3 or higher defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria
Time frame: From initial dose of study treatment and within 30 days of the last dose of study treatment (approximately 25 months)
Geometric Mean Concentration of Ipilimumab at End of Infusion (EOI)
Time frame: From Cycle 1, Day 1 to Cycle 4, Day 1 (approximately 9 weeks). Each cycle lasts 3 weeks. Cycle 1 day 1, Cycle 2 day 1 and Cycle 4 day 1 values reported.
Geometric Mean Concentration of Nivolumab at End of Infusion (EOI)
Time frame: From Cycle 1, Day 1 to Cycle 4, Day 1 (approximately 9 weeks). Each cycle lasts 3 weeks. Cycle 1 day 1, Cycle 2 day 1 and Cycle 4 day 1 values reported
Geometric Mean Trough Concentration of Ipilimumab
Time frame: From Cycle 2, Day 1 to Cycle 4, Day 1 (approximately 6 weeks). Each cycle lasts 3 weeks.
Geometric Mean Trough Concentration of Nivolumab
Time frame: From Cycle 2, Day 1 to Cycle 4, Day 1 (approximately 6 weeks). Each cycle lasts 3 weeks.
Objective Response Rate (ORR)
The ORR is defined as the proportion of participants with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR). The BOR is defined as the best response designation, as determined by the investigator, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of subsequent anti-cancer therapy, whichever occurs first.
Time frame: Week 12 following randomization, every 8 weeks for the first 12 months and then every 12 weeks until disease progression (approximately 20 months)
Progression Free Survival (PFS)
PFS is defined as the time between the date of randomization and the first date of documented progression, as determined by the investigator, or death due to any cause, whichever occurs first.
Time frame: From the date of randomization to the first date of documented progression (approximately 26 months)
| Milestone | Fixed Ratio Combination | Sequential Combination |
|---|---|---|
| Started | 53 | 53 |
| Completed | 24 | 30 |
| Not completed | 29 | 23 |
| Withdrew: Participant withdrew consent | 1 | 0 |
| Withdrew: Disease progression | 6 | 7 |
| Withdrew: Study drug toxicity | 22 | 16 |
| Milestone | Fixed Ratio Combination | Sequential Combination |
|---|---|---|
| Started | 24 | 30 |
| Completed | 20 | 22 |
| Not completed | 4 | 8 |
| Withdrew: Adverse event unrelated to study drug | 1 | 0 |
| Withdrew: Disease progression | 2 | 1 |
| Withdrew: Study drug toxicity | 0 | 4 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Participant withdrew consent | 0 | 1 |
| Withdrew: Adverse event | 1 | 1 |
| Milestone | Fixed Ratio Combination | Sequential Combination |
|---|---|---|
| Started | 20 | 22 |
| Completed | 8 | 14 |
| Not completed | 12 | 8 |
| Withdrew: Disease progression | 9 | 2 |
| Withdrew: Study drug toxicity | 3 | 4 |
| Withdrew: Maximum clinical benefit | 0 | 2 |
This outcome describes the percentage of participants experiencing at least 1 AE in the MedDRA Anaphylactic Reaction narrow scope SMQ. The narrow scope SMQ is composed of a large list of terms, including (but not limited to) anaphylactic shock and reaction, shock and shock symptoms, and circulatory collapse, among the others.
| Percent of Participants | Fixed Ratio Combination | Sequential Combination |
|---|---|---|
| Percentage of Participants Affected by AEs in the Narrow Scope MedDRA Anaphylactic Reaction SMQ | 0.0 (0.0 to 6.7) | 0.0 (0.0 to 6.7) |
This outcome describes the percentage of participants experiencing at least 1 AE in the Hypersensitivity/Infusion select AEs category. The select AEs consist of a list of preferred terms defined by the Sponsor and represent AEs with a potential immune-mediated etiology. The following 5 MedDRA preferred terms are included in the hypersensitivity/infusion reaction select AE category: Anaphylactic Reaction, Anaphylactic Shock, Bronchospasm, Hypersensitivity, and Infusion Related Reaction
| Percent of Participants | Fixed Ratio Combination | Sequential Combination |
|---|---|---|
| Percentage of Participants Affected by Hypersensitivity/Infusion Reaction Select AEs | 7.5 | 9.4 |
This outcome describes the percentage of participants who experienced at least 1 AE of Grade 3 or higher defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria
| Percent of participants | Fixed Ratio Combination | Sequential Combination |
|---|---|---|
| Percentage of Participants Affected by All Causality Grade 3 - 5 AEs | 69.8 | 56.6 |
This outcome describes the percentage of participants who experienced at least 1 Drug-related AE of Grade 3 or higher defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria
| Percent of participants | Fixed Ratio Combination | Sequential Combination |
|---|---|---|
| Percentage of Participants Affected by Drug-related Grade 3 - 5 AEs | 58.5 | 47.2 |
| micrograms per milliliter (ug/mL) | Fixed Ratio Combination | Sequential Combination |
|---|---|---|
| Cycle 1 Day 1 | 60.4 ± 93.0 | 61.5 ± 72.3 |
| Cycle 2 Day 1 | 66.8 ± 134 | 72.1 ± 71.8 |
| Cycle 4 Day 1 | 77.9 ± 94.2 | 84.6 ± 104 |
| micrograms per milliliter (ug/mL) | Fixed Ratio Combination | Sequential Combination |
|---|---|---|
| Cycle 1 Day 1 | 20.9 ± 77.3 | 21.8 ± 117 |
| Cycle 2 Day 1 | 24.2 ± 122 | 22.4 ± 101 |
| Cycle 4 Day 1 | 27.9 ± 79.8 | 27.4 ± 79.9 |
| micrograms per milliliter (ug/mL) | Fixed Ratio Combination | Sequential Combination |
|---|---|---|
| Cycle 2 Day 1 | 10.8 ± 30.2 | 9.94 ± 38.9 |
| Cycle 4 Day 1 | 16.5 ± 36.9 | 13.7 ± 46.0 |
| micrograms per milliliter (ug/mL) | Fixed Ratio Combination | Sequential Combination |
|---|---|---|
| Cycle 2 Day 1 | 3.94 ± 56.6 | 2.75 ± 65.9 |
| Cycle 4 Day 1 | 6.50 ± 44.6 | 4.05 ± 75.3 |
The ORR is defined as the proportion of participants with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR). The BOR is defined as the best response designation, as determined by the investigator, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of subsequent anti-cancer therapy, whichever occurs first.
| Percentage of Participants | Fixed Ratio Combination | Sequential Combination |
|---|---|---|
| Objective Response Rate (ORR) | 52.8 (38.6 to 66.7) | 60.4 (46.0 to 73.5) |
PFS is defined as the time between the date of randomization and the first date of documented progression, as determined by the investigator, or death due to any cause, whichever occurs first.
| Months | Fixed Ratio Combination | Sequential Combination |
|---|---|---|
| Progression Free Survival (PFS) | 10.25 (2.96 to NA) | NA (4.96 to NA) |
This outcome describes the percentage of participants experiencing at least 1 AE in the MedDRA Anaphylactic Reaction broad scope SMQ. Such AEs include any acute systemic reaction characterized by a large list of terms, including (but not limited to) pruritus, urticaria, flushing, hypotension, respiratory distress, and vascular insufficiency. It also includes other signs and symptoms such as asthma, choking sensation, coughing, sneezing, and difficulty breathing due to laryngeal spasm and/or bronchospasm. Less frequent clinical presentations are also captured and include hyperventilation, sensation of foreign body, and ocular edema.
| Percent of Participants | Fixed Ratio Combination | Sequential Combination |
|---|---|---|
| Percentage of Participants Affected by Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ) | 15.1 (6.7 to 27.6) | 17.0 (8.1 to 29.8) |
Collected over From first dose to 100 days following administration of the last dose (approximately 27 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fixed Ratio Combination | 14/53 (26.4%) | 35/53 (66%) | 51/53 (96.2%) |
| Sequential Combination | 14/53 (26.4%) | 35/53 (66%) | 51/53 (96.2%) |
| Event | Fixed Ratio Combination | Sequential Combination |
|---|---|---|
| PyrexiaGeneral disorders | 8/53 | 0/53 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/53 | 7/53 |
| Hepatocellular injuryHepatobiliary disorders | 6/53 | 3/53 |
| ColitisGastrointestinal disorders | 4/53 | 4/53 |
| Immune-mediated enterocolitisGastrointestinal disorders | 3/53 | 1/53 |
| VomitingGastrointestinal disorders | 3/53 | 1/53 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/53 | 1/53 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/53 | 3/53 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 3/53 | 1/53 |
| ThyroiditisEndocrine disorders | 2/53 | 1/53 |
| Event | Fixed Ratio Combination | Sequential Combination |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 16/53 | 25/53 |
| AstheniaGeneral disorders | 17/53 | 20/53 |
| PyrexiaGeneral disorders | 14/53 | 18/53 |
| PruritusSkin and subcutaneous tissue disorders | 9/53 | 17/53 |
| HeadacheNervous system disorders | 8/53 | 15/53 |
| RashSkin and subcutaneous tissue disorders | 15/53 | 12/53 |
| CoughRespiratory, thoracic and mediastinal disorders | 13/53 | 7/53 |
| NauseaGastrointestinal disorders | 9/53 | 12/53 |
| VomitingGastrointestinal disorders | 9/53 | 12/53 |
| HypothyroidismEndocrine disorders | 11/53 | 8/53 |
All treated participants
| Age, Continuous(years) | Fixed Ratio Combination | Sequential Combination | Total |
|---|---|---|---|
| Mean | 58.1 ± 14.5 | 56.3 ± 14.6 | 57.2 ± 14.5 |
| Sex: Female, Male(Participants) | Fixed Ratio Combination | Sequential Combination | Total |
|---|---|---|---|
| Female | 18 | 26 | 44 |
| Male | 35 | 27 | 62 |
| Ethnicity (NIH/OMB)(Participants) | Fixed Ratio Combination | Sequential Combination | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 26 | 28 | 54 |
| Unknown or Not Reported | 26 | 24 | 50 |
| Race (NIH/OMB)(Participants) | Fixed Ratio Combination | Sequential Combination | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 48 | 50 | 98 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 3 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2016 to primary completion in Oct 2017, 11 months.
Results were first posted in Jan 2019, 1 year 2 months after primary completion.
Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's 11 months is below that.
Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Ipilimumab